News articles about Baxter International (NYSE:BAX) have trended somewhat positive on Thursday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxter International earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 47.0137923167226 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Global Blood Plasma Market Anticipated Significant Growth by 2020 with CAGR of 10.54% (medgadget.com)
- Global Fluid Management Systems and Accessories Market 2018 – Baxter International, Inc., B. Braun Melsungen AG, Ecolab, Inc. (openpr.com)
- Baxter International Inc. (BAX) – Investors Alert on Unusual Volume Move – Wall Street Morning (wallstreetmorning.com)
- Hot Stock’s Watch List – Baxter International Inc (NYSE: BAX) – Stocks Pen (stockspen.com)
- Durable Medical Equipment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025 (markets.businessinsider.com)
Several analysts have commented on BAX shares. Royal Bank of Canada reissued a “hold” rating and set a $66.00 price target on shares of Baxter International in a research report on Wednesday, November 22nd. Bank of America reissued a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. JPMorgan Chase & Co. raised shares of Baxter International from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Finally, Evercore ISI started coverage on shares of Baxter International in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Baxter International presently has a consensus rating of “Buy” and a consensus target price of $71.00.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.05. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.77 billion. Baxter International had a net margin of 6.79% and a return on equity of 15.11%. Baxter International’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm posted $0.57 EPS. analysts anticipate that Baxter International will post 2.78 EPS for the current year.
Baxter International declared that its board has initiated a share repurchase program on Tuesday, February 20th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 2nd. Shareholders of record on Friday, March 2nd will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Thursday, March 1st. Baxter International’s dividend payout ratio is presently 26.89%.
In other Baxter International news, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total transaction of $1,918,947.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Carole J. Shapazian sold 4,990 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $66.05, for a total transaction of $329,589.50. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.